for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mayne Pharma Group Ltd

MYX.AX

Latest Trade

0.34AUD

Change

-0.01(-1.47%)

Volume

1,844,980

Today's Range

0.34

 - 

0.34

52 Week Range

0.26

 - 

0.59

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Latest Developments

Mayne Pharma Group Has Begun Distribution Of Isotretinoin Capsules In United States

Sept 29 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::HAS BEGUN DISTRIBUTION OF ISOTRETINOIN CAPSULES, 10 MG, 20 MG, 30 MG AND 40 MG IN UNITED STATES.

Mayne Pharma Says Frank Condella To Be Named Chairman

Aug 26 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::FRANK CONDELLA WILL BE APPOINTED CHAIRMAN.FRANK CONDELLA WILL BE APPOINTED CHAIRMAN WITH EFFECT FROM 30 SEPT.IAN SCHOLES WILL BE APPOINTED DEPUTY CHAIRMAN.

Mayne Pharma Group Says Co Served With A Class Action Proceeding In Supreme Court Of Victoria

Aug 3 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::SERVED WITH A CLASS ACTION PROCEEDING IN SUPREME COURT OF VICTORIA.

Mithra, Mayne Pharma's Nextstellis Receives FDA Marketing Exclusivity

May 27 (Reuters) - Mithra Pharmaceuticals SA <MITRA.BR>::NEXTSTELLIS RECEIVES FDA MARKETING EXCLUSIVITY AND PHASE III DATA PUBLISHED.EXCLUSIVITY RUNS FOR FIVE YEARS FROM FDA APPROVAL OF THE NEW DRUG APPLICATION FOR NEXTSTELLIS.

Mayne Pharma Group Says Nextstellis Granted Marketing Exclusivity From U.S. FDA

May 27 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::NOVEL ORAL CONTRACEPTIVE NEXTSTELLIS GRANTED MARKETING EXCLUSIVITY AS A NEW CHEMICAL ENTITY FROM US FDA.EXCLUSIVITY RUNS FOR FIVE YEARS FROM FDA APPROVAL OF NDA.

Mayne Pharma Group Says HY Underlying EBITDA Down 16%

Feb 24 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::HY UNDERLYING EBITDA $39.9M, DOWN 16%.HY REPORTED REVENUE $208.8 MILLION VERSUS $227.2 MILLION.

Mayne Pharma Group Says Ytd Group Revenue To Oct-End A$140 Million

Nov 24 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::YTD GROUP REVENUE TO OCT-END A$140 MILLION, DOWN 9% ON PCP.YTD UNDERLYING EBITDA TO OCT-END MARGINALLY ABOVE PRIOR CORRESPONDING PERIOD.

Mayne Pharma Group Says Chairman Roger Corbett To Step Down Within Next Twelve Months

Nov 9 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::ROGER CORBETT, CHAIRMAN WILL STEP DOWN FROM BOARD WITHIN NEXT TWELVE MONTHS.CORBETT WILL BE REPLACED BY US-BASED CHAIRMAN, CO TO APPOINT DEPUTY CHAIRMAN BASED IN AUSTRALIA.FOLLOWING FDA APPROVAL OF NEXTSTELLIS, MITHRA PHARMACEUTICALS WILL INCREASE ITS SHAREHOLDING FROM 4.95% TO 9.6%.MITHRA TO ALSO NOMINATE A NEW BOARD MEMBER AFTER RAISING STAKE.

Mayne Pharma Group Appoints Peter Paltoglou As CFO

Sept 29 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::APPOINTED PETER PALTOGLOU AS CHIEF FINANCIAL OFFICER.

Mayne Pharma FY Underlying EBITDA Falls 27%

Aug 21 (Reuters) - Mayne Pharma Group Ltd <MYX.AX>::FY REPORTED REVENUES OF $457.0M, DOWN 13% ON FY19.FY REPORTED EBITDA OF $80.3M, DOWN 28%.FY UNDERLYING EBITDA OF $95.3M, DOWN 27%.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up